Cost-Utility Analysis of First-Line Regimen between Cisplatin Plus Pemetrexed and Carboplatin plus Paclitaxel in Advanced Non-Squamous Non-Small-Cell Lung Cancer
Article Sidebar
Main Article Content
Abstract
Objective: To conduct cost-utility analysis of chemotherapy regimens, cisplatin plus pemetrexed (cis/pem) and carboplatin plus paclitaxel (cab/pac) in advanced non-squamous non-small cell lung cancer (NSCLC) in Thailand. Method: The researchers collected the data from patients aged 18 or above, diagnosed with NSCLC (stage IIIB and IV) and having performance status at 0 or 1, and being treated with either cis/pem or cab/pac at putpatient department at Maharaj Nakorn Chiang Mai hospital during Jan 1, 2012-June 30, 2013. The analysis was on based on the perspectives of providers and society. Cost in the study included direct medical cost and direct non-medical costs. The main outcome was quality adjusted time to disease progression (days). The study calculated incremental cost effective ratio in term of cost per quality-adjusted time to progression (days). The study conducted both one way and probabilistic sensitivity analyses were also performed. Result: Of the total 54 patients, 36 received cab/pac and 18 received cis/pem. Median time to disease progression was 119.94 days and 100.17 days for patients who received cis/pem and cab/pac, respectively. Quality-adjusted time to progression was 59.53 and 39.68 days for those with cis/pem and cab/pac, respectively. Total cost per patient with cis/pem and and cab/pac therapy was 423,798.52 THB and 119,324.46 THB, respectively. Quality adjusted-day to progression was 59.53 and 39.68 for patients who received cis/pem and cab/pac respectively. the incremental cost per quality adjusted time to progression (days) for cis/pem to cab/pac was 15,338.74 THB Conclusion: The use of cis/pem as first-line treatment for NSLC in Thailand is not cost effective when compared to the use of cab/pac.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Bureau of Policy and Strategy. Number and death rates per 100,000 population of first 10 leading cause groups of death (according to ICD mortality tabulation list1, 10th revision) 2006-2010 [online]. 2010 [cited 2011 Dec 18]. Available from: http://bps2.moph.go.th/sites/default/files/2.3.1_53.pdf.
3. Bureau of Policy and Strategy. Number of death and death rates per 100,000 population by age group sex and causes of death (according to ICD mortality tabulation list 1, 10th revision) [online]. 2010 [cited 2011 Dec 18]. Available from: http://bps2.moph.go.th/sites/default/files/moph_stat_53_2.3.3_53.pdf.
4. Information Technology Division, National Cancer Institute. Hospital-based cancer registry 2009 [online]. 2009 [cited 2011 Dec 18]. Available from: http://www.nci.go.th/th/File_download/Nci%20Cancer%20Registry/hospital%20based%20cancer%20registry.pdf.
5. National Health Security Office. Protocol for public compensate for lung cancer in the year in 2553 [online]. 2010 [cited 2011 Dec 18]. Available from: http://www.heart.kku.ac.th/office/nhso/Data_NHSO/Data_NHSO002.pdf.
6. Chaiwirawatthana A, Sukornyothin S, Konlak A, Khuhapema T. Approach to diagnosis and treatment of lung cancer [online]. 2009 [cited 2011 Dec 18]. Available from: http://www.dms.moph.go .th/dmsweb/cpgcorner/MA.pdf.
7. Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J ClinOncol. 2008; 26: 3543-51.
8. Information Technology Division, National Cancer Institute. Cancer in Thailand volume V, 2001-2003 [online]. 2010 [cited 2011 Dec 18]. Available from: http://www.nci.go.th/th/File_download/Nci%20Cancer%20Registry/Book%20Cancer%20In%20Thailand%202010%20for%20Web.pdf.
9. Ministry of Public Health. National list of essential medicines [online]. 2011 [cited 2011 Dec 18]. Available from: http://www.nlem.in.th/medicine/ essential/list.
10. Chaikledkaew U, Teerawattananon Y, Kongpitaya- chai S, Suksombun. Handbook for the assessment of health technology in Thailand. Nontaburi: the Graphico System; 2009.
11. Thongprasert S, Permsuwan U and Tongpak P. Utility of advanced non-samll-cell lung cancer patients in Thailand: preliminary study. Value Health 2012; 15: A657.
12. ERG Report. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) [online]. 2009 [cited 2012 Mar 7]. Available from: http://www.hta .ac.uk/erg/reports/1875.pdf
13. Klein R, Muehlenbien C, Liepa AM, et al. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009; 4: 1404-14.
14. Chanjaruporn F, Roughead EE, Sooksriwong C, et al. Budget impact analysis of premetrexed introduction: case study from a teaching hospital perspective, Thailand. J Med Assoc Thai 2011; 94: 1026-34.
